Vitamin D and Immune Mechanisms of Hypertension in Type 2 Diabetics
VDIM
1 other identifier
observational
40
1 country
2
Brief Summary
This trial will evaluate whether a particular type of circulating white blood cell, monocytes, from type 2 diabetics with high blood pressure and vitamin D deficiency vs. sufficiency will induce hormones that increase blood pressure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2017
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2017
CompletedFirst Submitted
Initial submission to the registry
October 23, 2017
CompletedFirst Posted
Study publicly available on registry
November 20, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
December 24, 2025
December 1, 2025
9.3 years
October 23, 2017
December 17, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Renin production by monocytes
Blood will be collected for isolation of monocytes. These cells will then be cultured to determine whether there is monocyte stimulation of a hormone that induces high blood pressure (renin) in kidney cells.
2 weeks
Secondary Outcomes (1)
Renin production by monocyte media
2 weeks
Study Arms (2)
Vitamin D Deficient
Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of \<20 ng/ml
Vitamin D Sufficient
Type 2 diabetics with high blood pressure and 25-hydroxyvitamin D levels of \>30 ng/ml
Interventions
Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.
Eligibility Criteria
T2DM patients with hypertension
You may qualify if:
- Type 2 diabetes (T2DM)
- Age: 25-80 years old
- Vitamin 25(OH)D3 levels \<20 or \>30 ng/ml.
- HbA1c: 5.5%-9.5%
- Blood Pressure: \<160/100 mm Hg on BP lowering medications and
- Blood Pressure: \>120/80 to 160/100 mmHg without BP lowering medications
You may not qualify if:
- Recent weight loss of more than 5% within 3 months prior to screening
- Current Pregnancy
- Hypercalcemia
- Previous heart attack and stroke
- Heart failure
- Atrial fibrillation
- Heavy alcohol consumption
- Extreme diets (Atkins, South Beach)
- Chronic renal failure: stage 4 or worse
- \>2 + proteinuria on urine sample
- Chronic diseases known to affect immunity
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Barnes-Jewish & Washington University Diabetes Center
St Louis, Missouri, 63110, United States
Washington University
St Louis, Missouri, 63110, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Carlos Bernal-Mizrachi, MD
Washington University School of Medicine
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 23, 2017
First Posted
November 20, 2017
Study Start
September 1, 2017
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
December 24, 2025
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will not share